Still sees 2025 non-GAAP gross margin on net product sales 86%.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REGN:
- Regeneron: Buy Rating Supported by Eylea Stability and Pipeline Potential
- Regeneron Initiates Promising Study on REGN7041 for Eye Inflammation
- Regeneron’s New Parkinson’s Study: A Potential Game-Changer?
- Regeneron’s New Phase 3 Study: A Potential Game Changer in VTE Prevention?
- Regeneron Pharmaceuticals Advances with ALN-CFB Study for PNH Treatment